It is well-known that estrogens immensely contribute to the progression of human breast carcinoma, but their detailed molecular mechanisms remain largely unclear. In this study, we identified nucleobindin 2 (NUCB2) as a gene associated with recurrence based on microarray data of estrogen receptor (ER)-positive breast carcinoma cases (n = 10), and subsequent in vitro study showed that NUCB2 expression was upregulated by estradiol in ER-positive MCF-7 cells. However, NUCB2 has not yet been examined in breast carcinoma, and its significance remains unknown. Therefore, we further examined the biological functions of NUCB2 in breast carcinoma using immunohistochemistry and in vitro studies. NUCB2 immunoreactivity was detected in carcinoma cells in 77 of 161 (48%) breast cancer cases, and positively associated with lymph node metastasis and ER status of the patients. In addition, NUCB2 status was significantly associated with an increased risk of recurrence and adverse clinical outcome of the patients using both univariate and multivariate analyses. Results of siRNA transfection experiments showed that NUCB2 significantly increased cell proliferation, and migration and invasion properties in both MCF-7 and ER-negative SK-BR-3 cells. These results suggest that NUCB2 is upregulated by estrogens and plays an important role, especially in the process of metastasis, in breast carcinomas. NUCB2 status is considered a potent prognostic factor in human breast cancer. (Cancer Sci 2012; 103: 136-143) B reast cancer is one of the most common malignancies in women. Estrogens play an important role in the progression of breast cancer through an interaction with ER, and ER is positive in approximately two-thirds of breast carcinoma cases. The great majority of ER-positive breast carcinomas respond to endocrine therapy such as tamoxifen and aromatase inhibitors, but it is also true that some of these carcinomas acquire clinical resistance to endocrine therapy. (1,2) Estrogen receptor activates the transcription of various target genes in a ligand-dependent manner by binding EREs located in the promoter region. Various estrogenic functions are characterized by the expression patterns of these genes, which make it extremely important to examine the expression and roles of estrogen-responsive genes to obtain a better understanding of estrogenic actions such as progression, recurrence, and resistance to endocrine therapy.(3) Various estrogen-responsive genes have been identified in breast carcinoma, (4,5) but their detailed clinical significance and ⁄ or function remain unclear in a great majority of these genes. Therefore, in this study, we first studied the expression profiles of genes containing ERE in ER-positive breast carcinoma tissues based on microarray data, and identified NUCB2 as a possible gene associated with recurrence in these patients.Nucleobindin 2 has a characteristic constitution of functional domains, such as a signal peptide, a Leu ⁄ Ile rich region, two Ca 2+ binding EF-hand domains separated by an acidic amino ...
Four mutations (C1939G, G3370T, 3746delG, and 4870delT) are relatively more prevalent in this population, accounting for 60% of the mutations in this study. This study revealed that the G3370T mutation was associated with milder forms of MM and the G3510A mutation was associated with a more severe form.
Runx2 has been proposed as one of the pivotal factors in the process of osteogenesis and metastasis in human malignancies including breast cancer, but its details have not been evaluated. Therefore, in this study, we evaluated its expression in human breast cancer using immunohistochemistry. One hundred and thirty-seven formalin-fixed and paraffin-embedded breast cancer specimens were used in this analysis of immunohistochemical study. Immunoreactivity was evaluated using the labeling index (LI). Runx2 immunoreactivity was detected in both carcinoma and stromal cells, as well as non-pathological ductal cells. The nuclear LI of Runx2 in carcinoma cells was associated with the clinical stage, histological grade and HER2 status of the patients examined. In addition, among the patients not associated with distant metastasis, those with high Runx2 LI demonstrated a significantly worse clinical outcome than those with a low LI. This was more pronounced in the group of estrogen receptor (ER)-negative cases. In addition, both univariate and multivariate analyses demonstrated that the Runx2 LI in breast carcinoma cells turned out an independent prognostic factor. Results of our present study demonstrated that Runx2 plays very important roles in the progression of breast cancer, especially in those of ER-negative cases. (Cancer Sci 2010; 101: 2670-2675 B reast cancer is one of the most common malignancies in women worldwide. Recently, the potential association of breast cancer with its bone metastasis has been evaluated from different perspectives and, in particular, the process of osteolysis itself in its metastatic sites has been proposed to facilitate breast cancer progression.(1) It is also well known that breast carcinoma cells themselves secrete parathyroid-hormone-related peptide (PTHrP), which stimulates osteoblasts in the microenvironment of bone metastatis.(2) Osteoblasts at the sites of metastasis are also considered to secrete a receptor activator of NFjB ligand (RANKL) to facilitate the process of transition from mesenchymal cells into functional osteoclasts, which subsequently resorb bone.(3-7) In normal human adult skeleton, bone is constantly renewed or maintained through the coordinated activities of both osteoclasts and osteoblasts.(8) Metastatic breast carcinoma cells are seeded into the bone microenvironment, which results in the maturation of osteoclasts.(9) These subsequently formed osteolytic foci are associated with bone resorption, which eventually leads to the release of growth factors including transforming growth factor-b (TGF-b) and several insulin-like growth factors (IGF) from the collapsed bone matrix.(10,11) These factors are considered to subsequently mediate tumor cell proliferation at the sites of bone metastasis.The Runt-related transcription factors 1-3 (Runxs1-3) have been shown to be required for the process of organogenesis, and mutations in these genes have been reported to be linked to several types of cancer development.(12) For instance, Runx1 and Runx3 mutations were reported...
The authors describe a patient with sporadic distal myopathy associated with reduced caveolin-3 in muscle fibers in which the muscle atrophy was restricted to the small muscles of the hands and feet. Gene analysis disclosed a heterozygous 80 G-->A substitution in the caveolin-3 gene that was identical to that of reported cases of elevated serum creatine kinase. This patient further demonstrated possible clinical heterogeneity of myopathies with mutations in the caveolin-3 gene.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.